Cholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigs

Lipids in Health and Disease

Volumn 3, Issue , 2004, Pages 1-12

  Berger, A ^a,b   Rein, D ^a,c   Kratky, E ^a   Monnard, I ^a   Hajjaj, H ^a,d   Meirim, I ^a   Piguet Welsch, C ^a   Hauser, J ^a,e   Mace, K ^a   Niederberger, P ^a  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

^b Clinical Data Inc   (United States)

^c BASF SE   (Germany)

^d UNIV LILLE   (France)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLESTANOL; CHOLESTEROL; CHOLIC ACID; COPROSTEROL; GANODERMA LUCIDUM EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LANOSTEROL DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; STEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; EX VIVO STUDY; FECES LEVEL; FEMALE; GANODERMA LUCIDUM; HAMSTER; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; MALE; NONHUMAN; SWINE;

ANIMALIA; BASIDIOMYCOTA; CRICETINAE; GANODERMA; GANODERMA LUCIDUM; SUS SCROFA;

EID: 2942514448     PISSN: 1476511X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-511X-3-1     Document Type: Article

References (79)

1. Borchers AT, Stern JS, Hackman RM, Keen CL, Gershwin ME: Mushrooms, tumors, and immunity. Proc Soc Exp Biol Med 1999, 221:281-293.
2. Kabir Y, Kimura S, Tamura T: Dietary effect of Ganoderma lucidum mushroom on blood pressure and lipid levels in spontaneously hypertensive rats (SHR). J Nutr Sci Vitaminol (Tokyo) 1988, 34:433-438.
3. Li Khva Ren, Vasil'ev AV, Orekhov AN, Tertov VV, Tutel'ian VA: [Anti-atherosclerotic properties of higher mushrooms (a clinico-experimental investigation)]. Vopr Pitan 1989:16-19.
4. Opletal L, Jahodar L, Chobot V, Zdansky P, Lukes J, Bratova M, Solichova D, Blunden G, Dacke CG, Patel AV: Evidence for the anti-hyperlipidaemic activity of the edible fungus Pleurotus ostreatus. Br J Biomed Sci 1997, 54:240-243.
5. Bobek P, Ozdin L, Galbavy S: Dose- and time-dependent hypocholesterolemic effect of oyster mushroom (Pleurotus ostreatus) in rats. Nutrition 1998, 14:282-286.
6. Bobek P, Galbavy S: Hypocholesterolemic and antiatherogenic effect of oyster mushroom (Pleurotus ostreatus) in rabbits. Nahrung 1999, 43:339-342.
7. Cheung PC, Lee MY: Fractionation and characterization of mushroom dietary fiber (nonstarch polysaccharides) as potential nutraceuticals from sclerotia of Pleurotus tuberregium (Fries) singer. J Agric Food Chem 2000, 48:3148-3151.
8. Gunde-Cimerman N, Plemenitas A: Hypocholesterolemic activity of the genus Pleurotus (Fr.) Karst. (Agaricales s.l., Basidiomycetes). Int J Medicinal Mushrooms 2001, 3:A91.
9. Cheung PC: Plasma and hepatic cholesterol levels and fecal neutral sterol excretion are altered in hamsters fed straw mushroom diets. J Nutr 1998, 128:1512-1516.
10. Fukushima M, Nakano M, Morii Y, Ohashi T, Fujiwara Y, Sonoyama K: Hepatic LDL receptor mRNA in rats is increased by dietary mushroom (Agaricus bisporus) fiber and sugar beet fiber. J Nutr 2000, 130:2151-2156.
11. Beynen AC, Fielmich AM, Lemmens AG, Terpstra AH: Farm-grown mushrooms (Agaricus campestris) in the diet of rats do not affect plasma and liver cholesterol concentrations. Nahrung 1996, 40:343-345.
12. Cheung PCK: The hypocholesterolemic effect of extracellular polysaccharide from the submerged fermentation of mushroom. Nutr Res 1996, 16:1953-1957.
13. Cheung PCK: The hypocholesterolemic effect of two edible mushroom: Auricularia auricula (Tree-ear) and Tremella fuci-formis (White-jelly leaf) in hypercholesterolemic rats. Nutr Res 1996, 16:1721-1725.
14. Kabir Y, Yamaguchi M, Kimura S: Effect of shiitake (Lentinus edodes) and maitake (Grifola frondosa) mushrooms on blood pressure and plasma lipids of spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo) 1987, 33:341-346.
15. Kubo K, Nanba H: The effect of maitake mushrooms on liver and serum lipids. Altern Ther Health Med 1996, 2:62-66.
16. Sugiyama K, Yamakawa A, Saeki S: Correlation of suppressed linoleic acid metabolism with the hypocholesterolemic action of eritadenine in rats. Lipids 1997, 32:859-866.
17. Sugiyama K, Kawagishi H, Tanaka A, Saeki S, Yoshida S, Sakamoto H, Ishiguro Y: Isolation of plasma cholesterol-lowering components from ningyotake (Polyporus confluens) mushroom. J Nutr Sci Vitaminol (Tokyo) 1992, 38:335-342.
18. Kaneda T, Tokuda S: Effect of various mushroom preparations on cholesterol levels in rats. J Nutr 1966, 90:371-376.
19. Shao G: [Treatment of hyperlipidemia with cultivated Cordyceps a double-blind, randomized placebo control trial]. Zhong Xi Yi Jie He Za Zhi (Chin J Integ Med) 1985, 5:642-665.
20. Tao J, Feng KY: Experimental and clinical studies on inhibitory effect of Ganoderma lucidum on platelet aggregation. J Tongji Med Univ 1990, 10:240-243.
21. Chang ST: Ganoderma - the leader in production and technology of mushroom neutraceuticals. In: Recent advances in Ganoderma lucidum research Edited by: Kim B-K, Kim YS. Seoul, Korea: The Pharmaceutical Society of Korea; 1995:43-52.
22. Chen AW, Miles PG: Biomedical research and the application of the mushroom nutriceuticals from Ganoderma lucidum. In: Mushroom Biology and Mushroom Products Edited by: Royse DJ. University Park, PA: The Pennsylvania State University; 1996:161-175.
23. Mizuno T: Oriental medicinal tradition of Ganoderma lucidum (Reishi) in China. In: Ganoderma lucidum Edited by: Mizuno T, Kim B-K. Seoul, Korea: II-Yang Pharm. Co. Ltd; 1996:101-106.
24. Sun-Soo T: Effective dosage of the extract of Ganoderma lucidum in the treatment of various ailments. In: Mushroom Biology and Mushroom Products Edited by: Royse DJ. University Park, PA: The Pennsylvania State University; 1996:177-185.
25. Wasser SP, Weis AL: Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 1999, 19:65-96.
26. Chang ST, Buswell JA: Medicinal Mushrooms - A Prominent Source of Nutriceuticals for the 21st century. Current Topics in Nutraceutical Research 2003, 1:257-280.
27. Shiao MS: Natural products of the medicinal fungus Ganoderma lucidum: occurrence, biological activities, and pharmacological functions. Chem Rec 2003, 3:172-180.
28. Lee SY, Rhee HM: Cardiovascular effects of mycelium extract of Ganoderma lucidum: inhibition of sympathetic outflow as a mechanism of its hypotensive action. Chem Pharm Bull (Tokyo) 1990, 38:1359-1364.
29. Rein D, Monnard I, German JB, Berger A: Screening of cholesterol absorption and synthesis inhibiting food ingredients in hamster models. FASEB J 2000, 14:A250.
30. Cevallos WH, Holmes WL, Myers RN, Smink RD: Swine in atherosclerosis research - Development of an experimental animal model and study of the effect of dietary fats on cholesterol metabolism. Atherosclerosis 1979, 34:303-317.
31. Clarkson T, Shively C, Weingand K: Animal Models of diet-Induced Atherosclerosis. In: Use of Animal Models for Research in Human Nutrition Volume 6. Edited by: Beynen A, West C.Basel: Karger; 1988:56-82.
32. Fadden K, Hill MJ, Latymer E, Low G, Owen RW: Steroid metabolism along the gastrointestinal tract of the cannulated pig. Eur J Cancer Prev 1999, 8:35-40.
33. Hikino H, Ishiyama M, Suzuki Y, Konno C: Mechanisms of hypoglycemic activity of ganoderan B: a glycan of Ganoderma lucidum fruit bodies. Planta Med 1989, 55:423-428.
34. Bao X, Duan J, Fang X, Fang J: Chemical modifications of the (1->3)-alpha-D-glucan from spores of Ganoderma lucidum and investigation of their physicochemical properties and immunological activity. Carbohydr Res 2001, 336:127-140.
35. Zhu M, Chang Q, Wong LK, Chong FS, Li RC: Triterpene antioxidants from Ganoderma lucidum. Phytother Res 1999, 13:529-531.
36. Wu TS, Shi LS, Kuo SC: Cytotoxicity of Ganoderma lucidum triterpenes. J Nat Prod 2001, 64:1121-1122.
37. Gao JJ, Min BS, Ahn EM, Nakamura N, Lee HK, Hattori M: New triterpene aldehydes, lucialdehydes A-C, from Ganoderma lucidum and their cytotoxicity against murine and human tumor cells. Chem Pharm Bull (Tokyo) 2002, 50:837-840.
38. Luo J, Zhao YY, Li ZB: A new lanostane-type triterpene from the fruiting bodies of Ganoderma lucidum. J Asian Nat Prod Res 2002, 4:129-134.
39. Ma J, Ye Q, Hua Y, Zhang D, Cooper R, Chang MN, Chang JY, Sun HH: New lanostanoids from the mushroom Ganoderma lucidum. J Nat Prod 2002, 65:72-75.
40. Komoda Y, Shimizu M, Sonoda Y, Sato Y: Ganoderic acid and its derivatives as cholesterol synthesis inhibitors. Chem Pharm Bull 1989, 37:531-533.
41. Mizushina Y, Takahashi N, Hanashima L, Koshino H, Esumi Y, Uzawa J, Sugawara F, Sakaguchi K: Lucidenic acid O and lactone, new terpene inhibitors of eukaryotic DNA polymerases from a basidiomycete, Ganoderma lucidum. Bioorg Med Chem 1999, 7: 2047-2052.
42. Ha TB, Gerhauser C, Zhang WD, Ho-Chong-Line N, Fouraste I: New lanostanoids from Ganoderma lucidum that induce NAD(P)H:quinone oxidoreductase in cultured murine hepatoma cells. Planta Med 2000, 66:681-684.
43. Walker KA, Kertesz DJ, Rotstein DM, Swinney DC, Berry PW, So OY, Webb AS, Watson DM, Mak AY, Burton PM et al.: Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering. J Med Chem 1993, 36:2235-2237.
44. Frye LL, Leonard DA: Lanosterol analogs: dual-action inhibitors of cholesterol biosynthesis. Crit Rev Biochem Mol Biol 1999, 34:123-140.
45. Bergstrom JD, Dufresne C, Bills GF, Nallin-Omstead M, Byrne K: Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase. Annu Rev Microbiol 1995, 49:607-639.
46. Bollen P, Ellegaard L: The Gottingen minipig in pharmacology and toxicology. Pharmacol Toxicol 1997, 80(Suppl 2):3-4.
47. Gunde-Cimerman N, Cimerman A: Pleurotus fruiting bodies contain the inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase-lovastatin. Exp Mycol 1995, 19:1-6.
48. Ogawa H, Hasumi K, Sakai K, Murakawa S, Endo A: Pannorin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor produced by Chrysosporium pannorum. J Antibiot (Tokyo) 1991, 44:762-767.
49. Morisaki M, Sonoda Y, Makino T, Ogihara N, Ikekawa N, Sato Y: Inhibitory effect of 15-oxygenated sterols on cholesterol synthesis from 24,25-dihydrolanosterol. J Biochem (Tokyo) 1986, 99:597-600.
50. 14DM) inhibitor which blocks electron transfer to the oxy-ferro intermediate. Biochim Biophys Acta 1987, 922:270-277.
51. Sonoda Y, Obi N, Onoda M, Sakakibara Y, Sato Y: Effects of 32-oxygenated lanosterol derivatives on 3-hydroxy-3-methylglu-taryl coenzyme A reductase activity and cholesterol biosynthesis from 24,25-dihydrolanosterol. Chem Pharm Bull (Tokyo) 1992, 40:2796-2799.
52. Trzaskos JM, Magolda RL, Favata MF, Fischer RT, Johnson PR, Chen HW, Ko SS, Leonard DA, Gaylor JL: Modulation of 3-hydroxy-3-methylglutaryl-CoA reductase by 15 alpha-fluorolanost-7-en-3 beta-ol. A mechanism-based inhibitor of cholesterol biosynthesis. J Biol Chem 1993, 268:22591-22599.
53. Morand OH, Aebi JD, Dehmlow H, Ji YH, Gains N, Lengsfeld H, Himber J: Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J Lipid Res 1997, 38:373-390.
54. Ness GC, Gertz KR, Holland RC: Regulation of hepatic lanosterol 14 alpha-demethylase gene expression by dietary cholesterol and cholesterol-lowering agents. Arch Biochem Biophys 2001, 395:233-238.
55. Conde K, Roy S, Freake HC, Newton RS, Fernandez ML: Atorvastatin and simvastatin have distinct effects on hydroxy methyl-glutaryl-CoA reductase activity and mRNA abundance in the guinea pig. Lipids 1999, 34:1327-1332.
56. Del Puppo M, Rauli S, Galli Kienle M: Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl-CoA reduct-ase in rats by simvastatin and pravastatin. Lipids 1995, 30:1057-1061.
57. Himber J, Missano B, Rudling M, Hennes U, Kempen HJ: Effects of stigmastanyl-phosphocholine (Ro 16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets. J Lipid Res 1995, 36:1567-1585.
58. Krause BR, Princen HM: Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis 1998, 140:15-24.
59. Ma PT, Gil G, Sudhof TC, Bilheimer DW, Goldstein JL, Brown MS: Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A 1986, 83:8370-8374.
60. Huff MW, Telford DE: Regulation of low density lipoprotein apoprotein B metabolism by lovastatin and cholestyramine in miniature pigs: effects on LDL composition and synthesis of LDL subfractions. Metabolism 1989, 38:256-264.
61. Tikkanen MJ: Statins: within-group comparisons, statin escape and combination therapy. Curr Opin Lipidol 1996, 7:385-388.
62. Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999, 341:498-511.
63. Berger A, Gremaud G, Baumgartner M, Rein D, Monnard I, Kratky E, Geiger W, Burri J, Dionisi F, Allan M, Lambelet P: Cholesterol-lowering properties of amaranth grain and oil in hamsters. Int J Vitam Nutr Res 2003, 73:39-47.
64. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW, Barrett P: Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler Thromb Vasc Biol 1997, 17:2589-2600.
65. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW: The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. Endocrinology 1999, 140:5293-5302.
66. Miettinen TA, Strandberg TE, Gylling H: Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol 2000, 20:1340-1346.
67. Collinder E, Cardona ME, Kozakova H, Norin E, Stern S, Midtvedt T: Biochemical intestinal parameters in pigs reared outdoors and indoors, and in germ-free pigs. J Vet Med A Physiol Pathol Clin Med 2002, 49:203-209.
68. Edwards PA, Kast HR, Anisfeld AM: BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res 2002, 43:2-12.
69. Davis RA, Miyake JH, Hui TY, Spann NJ: Regulation of cholesterol-7alpha-hydroxylase: BAREly missing a SHP. J Lipid Res 2002, 43:533-543.
70. Bobek P, Ozdin L, Kuniak L: The effect of oyster mushroom (Pleurotus ostreatus), its ethanolic extract and extraction residues on cholesterol levels in serum, lipoproteins and liver of rat. Nahrung 1995, 39:98-99.
71. Pfeifer AM, Cole KE, Smoot DT, Weston A, Groopman JD, Shields PG, Vignaud JM, Juillerat M, Lipsky MM, Trump BF et al.: Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci U S A 1993, 90:5123-5127.
72. Askenazi M, Driggers EM, Holtzman DA, Norman TC, Iverson S, Zimmer DP, Boers ME, Blomquist PR, Martinez EJ, Monreal AW et al.: Integrating transcriptional and metabolite profiles to direct the engineering of lovastatin-producing fungal strains. Nat Biotechnol 2003, 21:150-156.
73. Berlin E, Khan MA, Henderson GR, Kliman PG: Influence of age and sex on composition and lipid fluidity in miniature swine plasma lipoproteins. Atherosclerosis 1985, 54:187-203.
74. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW: Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J Lipid Res 1999, 40:1317-1328.
75. Ritskes-Hoitinga J, Bollen PJA: Nutrition of (Göttingen) minipigs: facts, assumptions and mysteries. Pharmacol Toxicol 1997, 80(Supl II):5-9.
76. Gremaud G, Piguet C, Baumgartner M, Pouteau E, Decarli B, Berger A, Fay LB: Simultaneous assessment of cholesterol absorption and synthesis in humans using on-line gas chromatography/combustion and gas chromatography/pyrolysis/isotope-ratio mass spectrometry. Rapid Commun Mass Spectrom 2001, 15:1207-1213.
77. Gremaud G, Dalan E, Piguet C, Baumgartner M, Ballabeni P, Decarli B, Leser ME, Berger A, Fay LB: Effects of non-esterified stanols in a liquid emulsion on cholesterol absorption and synthesis in hypercholesterolemic men. Eur J Nutr 2002, 41:54-60.
78. Nutrient Requirements for Swine - 10th Revised Edition. Washington, D. C.: National Research Council/National Academy of Science (NRC/NAS); 1998.
79. Shapiro JD, Nordstrom LJ, Mitschelen JJ, Rodwell VW, Schimke RT: Micro assay for 3-hydroxy-3-methylglutaryl-CoA reductase in rat liver and in L-cell fibroblast. Biochim Biophys Acta 1974, 370:369-377.